OSR Holdings, Inc.
OSRHNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | $2.9M | $3.5M | — | — | — |
| Operating income | −$18.3M | −$11.7M | −$1.8M | −$35,388 | −$3,308 |
| Net income | −$27.1M | −$2.4M | $403,780 | −$35,388 | −$3,308 |
| Total assets | $171.2M | $175.2M | $36.6M | $1.2M | $705,087 |
| Total liabilities | $44.2M | $32.0M | $4.1M | $1.3M | $707,207 |
| Equity | $127.0M | −$8.3M | −$3.9M | −$37,508 | −$2,120 |
| EPS (diluted) | $-0.80 | $-4.79 | $0.05 | $-0.01 | — |
| Shares out. | 19.3M | 5.6M | 9.1M | 1.7M | 1.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −631.0%
- Net margin
- −931.2%
- Return on equity
- −21.3%
- Return on assets
- −15.8%
- Return on capital (ROCE)
- −11.9%
- Liabilities / assets
- 25.8%
- Debt / equity
- 0.35×
- Book value / share
- $6.59
- Revenue growth (YoY)
- −17.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 1.04distress
- Accruals / assets
- −13.3%clean
- Beneish M-Score
- -2.11normal
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2025
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2024
- NT 10-Kmissed a reporting deadline ↗Apr 2, 2024
- NT 10-Qmissed a reporting deadline ↗May 16, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Joint Protein Central Inc.Passive (13G)Apr 22, 2026
- Bellevue Global Life Science Investors LlcPassive (13G)Feb 11, 2025
- Rivernorth Capital Management, LlcPassive (13G)Jan 10, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.3M | 1.0 | +2.3% |
| Apr 30, 2026 | 1.3M | 1.0 | +461.9% |
| Apr 15, 2026 | 228,151 | 1.0 | -75.1% |
| Mar 31, 2026 | 916,507 | 1.0 | +143.1% |
| Mar 13, 2026 | 376,966 | 1.0 | +42.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Regulation FD disclosureApr 30, 2026
- Director / officer changeApr 22, 2026
- Entered a material agreement · New financial obligation · Unregistered equity sale · Regulation FD disclosureApr 9, 2026
- Entered a material agreementApr 2, 2026
- Regulation FD disclosureMar 16, 2026
- Delisting / listing-standard noticeMar 10, 2026
- Completed an acquisition or disposition · Regulation FD disclosureJan 27, 2026
- Entered a material agreement · Regulation FD disclosureJan 14, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- DEF 14APROXY STATEMENTMay 26, 2026
- 10-QQUARTERLY REPORTMay 13, 2026
- PRE 14APROXY STATEMENTMay 11, 2026
- 8-K/AAMENDMENT NO. 1 TO FORM 8-KMay 6, 2026
- 8-KCURRENT REPORTApr 30, 2026
- SCHEDULE 13GApr 22, 2026
- 8-KCURRENT REPORTApr 22, 2026
- 3PRIMARY DOCUMENTApr 16, 2026
- 8-KCURRENT REPORTApr 9, 2026
- 8-K/AAMENDMENT NO. 1 TO FORM 8-KApr 3, 2026
- 8-KCURRENT REPORTApr 2, 2026
- 10-KANNUAL REPORTMar 31, 2026
- 8-KCURRENT REPORTMar 16, 2026
- 8-KCURRENT REPORTMar 10, 2026
- 8-KCURRENT REPORTJan 27, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.